Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment-resistant depression, offering a powerful alternative to traditional treatments. Researchers applied medical criteria to a national pool of patients and found that over half might be eligible for psilocybin therapy, pending FDA approval. If approved, this therapy could significantly impact public health policies, insurance frameworks, and economic costs by reducing reliance on long-term antidepressant prescriptions.
